解决基于肺癌的细胞外囊泡应用的挑战的最新进展
Recent advances to address challenges in extracellular vesicle-based applications for lung cancer
影响因子:14.60000
分区:医学1区 Top / 药学1区
发表日期:2024 Sep
作者:
Gaigai Huang, Wenshu Zheng, Yu Zhou, Meihua Wan, Tony Hu
摘要
肺癌高度流行，是全球癌症相关死亡的主要原因，由于缺乏对早期诊断和个性化治疗干预措施缺乏明确的肿瘤标记，这是一个重大挑战。最近，由于它们能够穿越生物屏障和提供多种生物货物，包括胞质蛋白，细胞表面蛋白，microRNA，microRNA，LNCRNA，circrna，dna和lipids，因此具有越来越多的细胞间通信载体（EVS）引起了越来越多的注意力。电动汽车越来越多地被认为是无创液体活检，药物输送平台的宝贵资源，以及用于肺癌精密医学的抗癌疫苗。在此，鉴于肿瘤相关的肺癌的诊断和治疗潜力，我们从转化的角度讨论了此主题。我们深入研究了电动汽车在肺癌致癌中起着的特定作用，并就高级工程技术如何克服当前的挑战和加快和/或增强电动汽车从实验室研究到临床环境的翻译提供了特定的观点。
Abstract
Lung cancer, highly prevalent and the leading cause of cancer-related death globally, persists as a significant challenge due to the lack of definitive tumor markers for early diagnosis and personalized therapeutic interventions. Recently, extracellular vesicles (EVs), functioning as natural carriers for intercellular communication, have received increasing attention due to their ability to traverse biological barriers and deliver diverse biological cargoes, including cytosolic proteins, cell surface proteins, microRNA, lncRNA, circRNA, DNA, and lipids. EVs are increasingly recognized as a valuable resource for non-invasive liquid biopsy, as well as drug delivery platforms, and anticancer vaccines for precision medicine in lung cancer. Herein, given the diagnostic and therapeutic potential of tumor-associated EVs for lung cancer, we discuss this topic from a translational standpoint. We delve into the specific roles that EVs play in lung cancer carcinogenesis and offer a particular perspective on how advanced engineering technologies can overcome the current challenges and expedite and/or enhance the translation of EVs from laboratory research to clinical settings.